Completion of the strategic combination between Novacap and PCAS and filing by Novacap of a draft simplified cash tender offer.
Novacap et PCAS (Euronext Paris: PCA, code ISIN FR0000053514), a technology-oriented fine chemical company, specialising in the development of processes and production of complex molecules for Life Sciences and Specialty Chemicals Markets, are finalising the strategic combination of the two groups which was announced on 15 May 2017.
Today (June 21st, 2017), Novacap acquired blocks of shares representing a total of 51.80% of PCAS’ share capital and 50.96% of its voting rights, after the PCAS Central Works Council issued an opinion on 15 June 2017 in favour of Novacap taking control of PCAS and following the authorisation of the transaction by the French, Irish, Austrian and German competition authorities. The blocks of shares were acquired at the price of 17 euros per share (including the outstanding dividend balance due in respect of the financial year ended 31 December 2016).
This combination will create a global leader in the pharmaceutical synthesis and fine specialty chemicals industry, with an international footprint, a large products portfolio and an extensive range of technologies.